Hemodialysis patients with secondary hyperparathyroidism have higher rates of mortality, readmission, and reoperation than those with primary hyperparathyroidism, so parathyroidectomy is associated with higher costs, according to investigators.
Parathyroid hormone levels declined in the 6 months after patients received microwave ablation, a meta-analysis finds.
In a study, CKD patients with vitamin D insufficiency had greater reductions in proteinuria severity after receiving low-dose calcitriol with RAAS blockade.
An Italian study of dialysis patients with secondary hyperparathyroidism found a 19% lower all-cause hospitalization rate for high vs low adherers to cinacalcet.
In a study of hemodialysis patients, similar proportions of thrice-weekly and once-daily cinacalcet users achieved PTH levels of less than 600 pg/mL within 6 months.
A biological link between bone metabolism and vascular calcification has long been hypothesized.
In a study of hemodialysis patients, certain CKD-MBD factors were significantly associated with greater mortality risk at any iPTH level.
In a case-control study, unintentional weight loss within 6 months emerged as a new calciphylaxis risk factor in hemodialysis patients.
Hyperkalemia, hypomagnesemia, and hyperparathyroidism commonly persist after kidney transplant surgery.
Maintenance hemodialysis patients with SHPT who switched from IV vitamin D analogs to oral calcitriol had similar serum levels of iPTH, calcium, and phosphate at 12 months as those who continued on the IV treatment.